查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1701282

急性骨髓性白血病治疗市场规模、份额、趋势分析报告：按疾病、治疗、给药途径、最终用途、地区和细分市场进行预测，2025 年至 2030 年

Acute Myeloid Leukemia Treatment Market Size, Share & Trends Analysis Report By Disease, By Treatment (Chemotherapy, Targeted Therapy, Immunotherapy), By Route of Administration, By End Use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

市场规模和趋势

预计2024年全球急性骨髓性白血病治疗市场规模为34.7亿美元，2025年至2030年复合年增长率为10.6%。

急性骨髓性白血病发病率的上升和对先进治疗的需求的不断增长是由于基因突变、不健康的生活方式、持续接触苯等有害化学物质以及辐射暴露等因素造成的。此外，老龄人口的增加和未满足的需求的增加预计将进一步推动市场成长。

急性骨髓性白血病（AML）治疗的进展迄今一直处于标靶治疗进展的前沿。最近的趋势包括 BCL2 抑制剂、IDH 抑制剂和 FLT3 抑制剂的重大发展。这些治疗方法针对特定的基因突变提供个人化的治疗方案，进而改善患者的治疗效果。例如，对于新诊断的 FLT3-ITD 阳性急性骨髓性白血病患者，FDA 于 2023 年 7 月在美国核准了quizartinib（Vanflita），为标准化疗提供了额外的治疗选择。

将Venetoclax与Azacitidine和其他甲基转移酶抑制剂联合治疗，已显示出提高 AML 患者存活率的良好效果。此外，研究也致力于将Venetoclax纳入传统的7+3化疗方案中，以最大限度地提高治疗效果。这些创新方法显示人们越来越致力于开发多方面的治疗策略，以改善患者的治疗效果。

此外，包括 CAR-T 细胞疗法在内的免疫疗法趋势代表了 AML 治疗的改变趋势。这些治疗方法旨在增强免疫系统对癌细胞的反应，为选择有限的患者带来新的希望。对 AML 相关基因改变的深入了解带来了进一步的个人化治疗策略，例如使用 menin 抑制剂针对 KMT2A 和 NPM1 中的特定突变。

由于基因突变、不良生活习惯和环境危害等因素导致 AML 发病率不断上升，凸显了对创新治疗方法的迫切需求。根据美国癌症协会估计，2025 年将有约 22,010 人被诊断出患有 AML，这进一步凸显了对有效治疗方案日益增长的需求。 2023年12月，蒙特娄大学的科学家获得加拿大基因组组织600万美元的津贴，用于为高急性骨髓性白血病患者开发一种新型细胞週期细胞週期蛋白K降解剂。针对高风险患者的创新治疗方法的开发以及全球对研发的大量投资预计将推动市场成长。此外，製药公司和研究机构之间的合作正在加快开发新的 AML 治疗方法的步伐。

目录

第一章调查方法与范围

第二章执行摘要

第三章急性骨髓性白血病治疗市场变数、趋势与范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析—波特五力分析
    • PESTLE分析
  • 管道分析

第四章急性骨髓性白血病治疗市场：疾病业务分析

  • 2024年及2030年的疾病市场占有率
  • 疾病细分仪表板
  • 市场规模、预测与趋势分析（按治疗，2018-2030 年）
  • 骨髓性白血病
  • 粒单核细胞白血病
  • 早幼粒细胞白血病
  • 单核细胞白血病
  • 其他的

第五章急性骨髓性白血病治疗市场：治疗业务分析

  • 2024年和2030年的治疗市场占有率
  • 治疗细分仪表板
  • 市场规模、预测与趋势分析（按治疗，2018-2030 年）
  • 化疗
  • 标靶治疗
  • 免疫疗法
  • 其他的

第六章急性骨髓性白血病治疗市场：给药途径业务分析

  • 2024 年及 2030 年给药途径市场占有率
  • 给药途径细分仪表板
  • 按管理路线分類的市场规模、预测和趋势分析（2018-2030 年）
  • 肠外
  • 口服

第七章急性骨髓性白血病治疗市场：最终用途业务分析

  • 2024 年及 2030 年最终用途市场占有率
  • 最终用途细分仪表板
  • 按最终用途分類的市场规模、预测和趋势分析（2018-2030 年）
  • 医院和诊所
  • 专业中心
  • 居家照护环境
  • 门诊治疗中心

第八章急性骨髓性白血病治疗市场：区域、估计和趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 2018-2030年市场规模、预测趋势分析
  • 北美洲
    • 2018-2030年各国情况
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 2018-2030年各国情况
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 丹麦
    • 瑞典
  • 亚太地区
    • 2018-2030年各国情况
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 2018-2030年各国情况
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 2018-2030年各国情况
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第九章竞争格局

  • 参与者概述
  • 企业市场分析
  • 公司分类
  • 战略地图
  • 公司简介/上市公司
    • Astellas Pharma Inc.
    • Bristol-Myers Squibb Company
    • DAIICHI SANKYO COMPANY, LIMITED
    • Jazz Pharmaceuticals plc
    • Novartis AG
    • Otsuka Pharmaceuticals Co.,Ltd.
    • Pfizer Inc.
    • Rigel Pharmaceuticals, Inc.
    • Merck KGaA
    • Sanofi
Product Code: GVR-4-68040-384-0

Market Size & Trends:

The global acute myeloid leukemia treatment market size was estimated at USD 3.47 billion in 2024 and is projected to grow at a CAGR of 10.6% from 2025 to 2030. Rising incidences of acute myeloid leukemia and increasing need for advanced therapeutics are attributed to factors such as genetic mutations, unhealthy lifestyles, continued exposure to hazardous chemicals such as benzene, and radiation exposure. Moreover, the increasing geriatric population base and growing unmet healthcare needs are expected to boost market growth further.

Advancements in targeted therapies have been at the forefront of the progress in Acute Myeloid Leukemia (AML) treatment so far. In recent years, there has been substantial development in therapies such as BCL2 inhibitors, IDH inhibitors, and FLT3 inhibitors. These therapies provide personalized treatment options tailored to specific genetic mutations, resulting in improved outcomes for patients. For instance, in July 2023, the FDA approved quizartinib (Vanflyta) for newly diagnosed FLT3-ITD positive acute myeloid leukemia in the U.S., enhancing treatment options alongside standard chemotherapy.

Combinations such as venetoclax with azacitidine or other hypomethylating agents have shown promising results in enhancing survival rates for AML patients. Additional research interest focuses on incorporating venetoclax into the traditional 7+3 chemotherapy regimen, which aims to maximize treatment efficacy. Such innovative approaches indicate a growing commitment to developing multifaceted treatment strategies that promise to improve patient outcomes.

Moreover, the exploration of immunotherapies, including CAR-T cell therapies, represents a transformative trend in AML treatment. These therapies are designed to bolster the immune system's response to cancer cells, thus providing new hope for patients who have limited options. The advancements in the understanding of genetic mutations associated with AML have further contributed to personalized treatment strategies, such as targeting specific mutations such as KMT2A and NPM1 with menin inhibitors.

The growing incidence of AML, driven by factors such as genetic mutations, unhealthy lifestyles, and environmental hazards, underscores the urgent need for innovative therapies. According to the American Cancer Society, approximately 22,010 individuals are estimated to be diagnosed with AML in 2025, further highlighting the rising demand for effective treatment options. In December 2023, scientists at the University of Montreal secured a USD 6 million grant from Genome Canada to develop a novel Cyclin K degrader for high-risk acute myeloid leukemia patients, aiming to enhance treatment outcomes and stimulate economic growth in Canada. The development of innovative therapies for high-risk patients, along with substantial global investments in research and development, is expected to drive market growth. Furthermore, partnerships between pharmaceutical companies and research institutions are enhancing the pace of new AML treatment development.

Global Acute Myeloid Leukemia Treatment Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global acute myeloid leukemia treatment market report based on disease, treatment, route of administration, end use, and region:

  • Disease Outlook (Revenue, USD Million, 2018 - 2030)
  • Myeloblastic Leukemia
  • Myelomonocytic Leukemia
  • Promyelocytic Leukemia
  • Monocytic Leukemia
  • Other Diseases
  • Treatment Outlook (Revenue, USD Million, 2018 - 2030)
  • Chemotherapy
    • Anti-metabolites
    • Alkylating Agents
    • Anthracycline Drugs
    • Others
  • Targeted Therapy
    • FLT3 Inhibitors
    • Rydapt
    • Vanflyta
    • Xospata
    • IDH Inhibitors
    • Tibsovo
    • Rezlidhia
    • Idhifa
    • Mylotarg
    • BCL-2 Inhibitor
    • Hedgehog Pathway Inhibitor
  • Immunotherapy
    • Bispecific Antibodies
    • Antibody-drug Conjugates
    • Immune Checkpoint Inhibitors
    • Chimeric Antigen Receptor (CAR) T-cell Therapy
  • Other Treatments
  • Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
  • Parenteral
  • Oral
  • End Use Outlook (Revenue, USD Million, 2018 - 2030)
  • Hospitals and Clinics
  • Specialty Centers
  • Homecare Setting
  • Ambulatory Care Centers
  • Regional Outlook (Revenue, USD Million, 2018 - 2030)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Disease
    • 1.2.2. Treatment
    • 1.2.3. Route of Administration
    • 1.2.4. End Use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Acute Myeloid Leukemia Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
  • 3.4. Pipeline Analysis

Chapter 4. Acute Myeloid Leukemia Treatment Market: Disease Business Analysis

  • 4.1. Disease Market Share, 2024 & 2030
  • 4.2. Disease Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
  • 4.4. Myeloblastic Leukemia
    • 4.4.1. Myeloblastic Leukemia Market, 2018 - 2030 (USD Million)
  • 4.5. Myelomonocytic Leukemia
    • 4.5.1. Myelomonocytic Leukemia Market, 2018 - 2030 (USD Million)
  • 4.6. Promyelocytic Leukemia
    • 4.6.1. Promyelocytic Leukemia Market, 2018 - 2030 (USD Million)
  • 4.7. Monocytic Leukemia
    • 4.7.1. Monocytic Leukemia Market, 2018 - 2030 (USD Million)
  • 4.8. Other Diseases
    • 4.8.1. Other Diseases Market, 2018 - 2030 (USD Million)

Chapter 5. Acute Myeloid Leukemia Treatment Market: Treatment Business Analysis

  • 5.1. Treatment Market Share, 2024 & 2030
  • 5.2. Treatment Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
  • 5.4. Chemotherapy
    • 5.4.1. Chemotherapy Market, 2018 - 2030 (USD Million)
    • 5.4.2. Anti-metabolites
    • 5.4.3. Anti-metabolites Market, 2018 - 2030 (USD Million)
    • 5.4.4. Alkylating Agents
    • 5.4.5. Alkylating Agents Market, 2018 - 2030 (USD Million)
    • 5.4.6. Anthracycline Drugs
    • 5.4.7. Anthracycline Drugs Market, 2018 - 2030 (USD Million)
    • 5.4.8. Others
    • 5.4.9. Others Market, 2018 - 2030 (USD Million)
  • 5.5. Targeted Therapy
    • 5.5.1. Targeted Therapy Market, 2018 - 2030 (USD Million)
    • 5.5.2. FLT3 Inhibitors
    • 5.5.3. FLT3 Inhibitors Market, 2018 - 2030 (USD Million)
      • 5.5.3.1. Rydapt
        • 5.5.3.1.1. Rydapt Market, 2018 - 2030 (USD Million)
      • 5.5.3.2. Vanflyta
        • 5.5.3.2.1. Vanflyta Market, 2018 - 2030 (USD Million)
      • 5.5.3.3. Xospata
        • 5.5.3.3.1. Xospata Market, 2018 - 2030 (USD Million)
    • 5.5.4. IDH Inhibitors
    • 5.5.5. IDH Inhibitors Market, 2018 - 2030 (USD Million)
      • 5.5.5.1. Tibsovo
        • 5.5.5.1.1. Tibsovo Market, 2018 - 2030 (USD Million)
      • 5.5.5.2. Rezlidhia
        • 5.5.5.2.1. Rezlidhia Market, 2018 - 2030 (USD Million)
      • 5.5.5.3. Idhifa
        • 5.5.5.3.1. Idhifa Market, 2018 - 2030 (USD Million)
    • 5.5.6. Mylotarg
      • 5.5.6.1. Mylotarg Market, 2018 - 2030 (USD Million)
    • 5.5.7. BCL-2 Inhibitor
      • 5.5.7.1. BCL-2 Inhibitor Market, 2018 - 2030 (USD Million)
    • 5.5.8. Hedgehog Pathway Inhibitor
      • 5.5.8.1. Hedgehog Pathway Inhibitor Market, 2018 - 2030 (USD Million)
  • 5.6. Immunotherapy
    • 5.6.1. Immunotherapy Market, 2018 - 2030 (USD Million)
    • 5.6.2. Bispecific Antibodies
      • 5.6.2.1. Bispecific Antibodies Market, 2018 - 2030 (USD Million)
    • 5.6.3. Antibody-drug Conjugates
      • 5.6.3.1. Antibody-drug Conjugates Market, 2018 - 2030 (USD Million)
    • 5.6.4. Immune Checkpoint Inhibitors
      • 5.6.4.1. Immune Checkpoint Inhibitors Market, 2018 - 2030 (USD Million)
    • 5.6.5. Chimeric Antigen Receptor (CAR) T-cell Therapy
      • 5.6.5.1. Chimeric Antigen Receptor (CAR) T-cell Therapy Market, 2018 - 2030 (USD Million)
  • 5.7. Other Treatments
    • 5.7.1. Other Treatments Market, 2018 - 2030 (USD Million)

Chapter 6. Acute Myeloid Leukemia Treatment Market: Route of Administration Business Analysis

  • 6.1. Route of Administration Market Share, 2024 & 2030
  • 6.2. Route of Administration Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
  • 6.4. Parenteral
    • 6.4.1. Parenteral Market, 2018 - 2030 (USD Million)
  • 6.5. Oral
    • 6.5.1. Oral Market, 2018 - 2030 (USD Million)

Chapter 7. Acute Myeloid Leukemia Treatment Market: End Use Business Analysis

  • 7.1. End Use Market Share, 2024 & 2030
  • 7.2. End Use Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 7.4. Hospitals and Clinics
    • 7.4.1. Hospitals and Clinics Market, 2018 - 2030 (USD Million)
  • 7.5. Specialty Centers
    • 7.5.1. Specialty Centers Market, 2018 - 2030 (USD Million)
  • 7.6. Homecare Setting
    • 7.6.1. Homecare Setting Market, 2018 - 2030 (USD Million)
  • 7.7. Ambulatory Care Centers
    • 7.7.1. Ambulatory Care Centers Market, 2018 - 2030 (USD Million)

Chapter 8. Acute Myeloid Leukemia Treatment Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.4. North America
    • 8.4.1. North America Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Regulatory Framework
      • 8.4.2.3. Competitive Insights
      • 8.4.2.4. U.S. Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Regulatory Framework
      • 8.4.3.3. Competitive Insights
      • 8.4.3.4. Canada Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Regulatory Framework
      • 8.4.4.3. Competitive Insights
      • 8.4.4.4. Mexico Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Regulatory Framework
      • 8.5.2.3. Competitive Insights
      • 8.5.2.4. UK Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Regulatory Framework
      • 8.5.3.3. Competitive Insights
      • 8.5.3.4. Germany Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Regulatory Framework
      • 8.5.4.3. Competitive Insights
      • 8.5.4.4. France Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Regulatory Framework
      • 8.5.5.3. Competitive Insights
      • 8.5.5.4. Italy Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Regulatory Framework
      • 8.5.6.3. Competitive Insights
      • 8.5.6.4. Spain Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.7. Norway
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Regulatory Framework
      • 8.5.7.3. Competitive Insights
      • 8.5.7.4. Norway Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.8. Denmark
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Regulatory Framework
      • 8.5.8.3. Competitive Insights
      • 8.5.8.4. Denmark Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.9. Sweden
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Regulatory Framework
      • 8.5.9.3. Competitive Insights
      • 8.5.9.4. Sweden Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Regulatory Framework
      • 8.6.2.3. Competitive Insights
      • 8.6.2.4. Japan Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Regulatory Framework
      • 8.6.3.3. Competitive Insights
      • 8.6.3.4. China Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Regulatory Framework
      • 8.6.4.3. Competitive Insights
      • 8.6.4.4. India Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. South Korea
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Regulatory Framework
      • 8.6.5.3. Competitive Insights
      • 8.6.5.4. South Korea Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.6. Australia
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Regulatory Framework
      • 8.6.6.3. Competitive Insights
      • 8.6.6.4. Australia Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Regulatory Framework
      • 8.6.7.3. Competitive Insights
      • 8.6.7.4. Thailand Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Regulatory Framework
      • 8.7.2.3. Competitive Insights
      • 8.7.2.4. Brazil Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Regulatory Framework
      • 8.7.3.3. Competitive Insights
      • 8.7.3.4. Argentina Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.8. MEA
    • 8.8.1. MEA Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Regulatory Framework
      • 8.8.2.3. Competitive Insights
      • 8.8.2.4. South Africa Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Regulatory Framework
      • 8.8.3.3. Competitive Insights
      • 8.8.3.4. Saudi Arabia Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Regulatory Framework
      • 8.8.4.3. Competitive Insights
      • 8.8.4.4. UAE Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Regulatory Framework
      • 8.8.5.3. Competitive Insights
      • 8.8.5.4. Kuwait Acute Myeloid Leukemia Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. Astellas Pharma Inc.
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. Bristol-Myers Squibb Company
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. DAIICHI SANKYO COMPANY, LIMITED
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. Jazz Pharmaceuticals plc
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Novartis AG
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. Otsuka Pharmaceuticals Co.,Ltd.
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. Pfizer Inc.
      • 9.5.7.1. Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. Rigel Pharmaceuticals, Inc.
      • 9.5.8.1. Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. Merck KGaA
      • 9.5.9.1. Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. Sanofi
      • 9.5.10.1. Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Product Benchmarking
      • 9.5.10.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global acute myeloid leukemia treatment market, by region, 2018 - 2030 (USD Million)
  • Table 4. Global acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 5. Global acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 6. Global acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 7. Global acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 8. North America acute myeloid leukemia treatment market, by country, 2018 - 2030 (USD Million)
  • Table 9. North America acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 10. North America acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 11. North America acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 12. North America acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 13. U.S. acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 14. U.S. acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 15. U.S. acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 16. U.S. acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 17. Canada acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 18. Canada acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 19. Canada acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 20. Canada acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 21. Mexico acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 22. Mexico acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 23. Mexico acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 24. Mexico acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 25. Europe acute myeloid leukemia treatment market, by country, 2018 - 2030 (USD Million)
  • Table 26. Europe acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 27. Europe acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 28. Europe acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 29. Europe acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 30. UK acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 31. UK acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 32. UK acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 33. UK acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 34. Germany acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 35. Germany acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 36. Germany acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 37. Germany acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 38. France acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 39. France acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 40. France acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 41. France acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 42. Italy acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 43. Italy acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 44. Italy acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 45. Italy acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 46. Spain acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 47. Spain acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 48. Spain acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 49. Spain acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 50. Denmark acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 51. Denmark acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 52. Denmark acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 53. Denmark acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 54. Sweden acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 55. Sweden acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 56. Sweden acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 57. Sweden acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 58. Norway acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 59. Norway acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 60. Norway acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 61. Norway acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 62. Asia Pacific acute myeloid leukemia treatment market, by country, 2018 - 2030 (USD Million)
  • Table 63. Asia Pacific acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 64. Asia Pacific acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 65. Asia Pacific acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 66. Asia Pacific acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 67. China acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 68. China acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 69. China acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 70. China acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 71. Japan acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 72. Japan acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 73. Japan acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 74. Japan acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 75. India acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 76. India acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 77. India acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 78. India acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 79. Australia acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 80. Australia acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 81. Australia acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 82. Australia acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 83. South Korea acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 84. South Korea acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 85. South Korea acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 86. South Korea acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 87. Thailand acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 88. Thailand acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 89. Thailand acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 90. Thailand acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 91. Latin America acute myeloid leukemia treatment market, by country, 2018 - 2030 (USD Million)
  • Table 92. Brazil acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 93. Brazil acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 94. Brazil acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 95. Brazil acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 96. Argentina acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 97. Argentina acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 98. Argentina acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 99. Argentina acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 100. Latin America acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 101. Latin America acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 102. Latin America acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 103. Latin America acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 104. Middle East & Africa Acute myeloid leukemia treatment market, by country, 2018 - 2030 (USD Million)
  • Table 105. Middle East & Africa acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 106. Middle East & Africa acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 107. Middle East & Africa acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 108. Middle East & Africa acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 109. South Africa acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 110. South Africa acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 111. South Africa acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 112. South Africa acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 113. Saudi Arabia acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 114. Saudi Arabia acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 115. Saudi Arabia acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 116. Saudi Arabia acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 117. UAE acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 118. UAE acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 119. UAE acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 120. UAE acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 121. Kuwait acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 122. Kuwait acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 123. Kuwait acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 124. Kuwait acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Acute myeloid leukemia treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Treatment and route of administration outlook (USD Million)
  • Fig. 10 End use outlook (USD Million)
  • Fig. 11 Competitive landscape
  • Fig. 12 Acute myeloid leukemia treatment market dynamics
  • Fig. 13 Acute myeloid leukemia treatment market: Porter's five forces analysis
  • Fig. 14 Acute myeloid leukemia treatment market: PESTLE analysis
  • Fig. 15 Acute myeloid leukemia treatment market: Disease segment dashboard
  • Fig. 16 Acute myeloid leukemia treatment market: Disease market share analysis, 2024 & 2030
  • Fig. 17 Myeloblastic leukemia market, 2018 - 2030 (USD Million)
  • Fig. 18 Myelomonocytic leukemia market, 2018 - 2030 (USD Million)
  • Fig. 19 Promyelocytic leukemia market, 2018 - 2030 (USD Million)
  • Fig. 20 Monocytic leukemia market, 2018 - 2030 (USD Million)
  • Fig. 21 Other diseases market, 2018 - 2030 (USD Million)
  • Fig. 22 Acute myeloid leukemia treatment market: Treatment segment dashboard
  • Fig. 23 Acute myeloid leukemia treatment market: Treatment market share analysis, 2024 & 2030
  • Fig. 24 Chemotherapy market, 2018 - 2030 (USD Million)
  • Fig. 25 Anti-metabolites market, 2018 - 2030 (USD Million)
  • Fig. 26 Alkylating agents market, 2018 - 2030 (USD Million)
  • Fig. 27 Anthracycline drugs market, 2018 - 2030 (USD Million)
  • Fig. 28 Others market, 2018 - 2030 (USD Million)
  • Fig. 29 Targeted therapy market, 2018 - 2030 (USD Million)
  • Fig. 30 FLT3 inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 31 Rydapt market, 2018 - 2030 (USD Million)
  • Fig. 32 Vanflyta market, 2018 - 2030 (USD Million)
  • Fig. 33 Xospata market, 2018 - 2030 (USD Million)
  • Fig. 34 IDH inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 35 Tibsovo market, 2018 - 2030 (USD Million)
  • Fig. 36 Rezlidhia market, 2018 - 2030 (USD Million)
  • Fig. 37 Idhifa market, 2018 - 2030 (USD Million)
  • Fig. 38 Mylotarg market, 2018 - 2030 (USD Million)
  • Fig. 39 BCL-2 inhibitor market, 2018 - 2030 (USD Million)
  • Fig. 40 Hedgehog pathway inhibitor market, 2018 - 2030 (USD Million)
  • Fig. 41 Immunotherapy market, 2018 - 2030 (USD Million)
  • Fig. 42 Bispecific antibodies market, 2018 - 2030 (USD Million)
  • Fig. 43 Antibody-drug conjugates market, 2018 - 2030 (USD Million)
  • Fig. 44 Immune checkpoint inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 45 Chimeric Antigen Receptor (CAR) T-cell therapy market, 2018 - 2030 (USD Million)
  • Fig. 46 Other treatments market, 2018 - 2030 (USD Million)
  • Fig. 47 Acute myeloid leukemia treatment market: Route of administration segment dashboard
  • Fig. 48 Acute myeloid leukemia treatment market: Route of administration market share analysis, 2024 & 2030
  • Fig. 49 Parenteral market, 2018 - 2030 (USD Million)
  • Fig. 50 Oral market, 2018 - 2030 (USD Million)
  • Fig. 51 Acute myeloid leukemia treatment market: End use segment dashboard
  • Fig. 52 Acute myeloid leukemia treatment market: End use market share analysis, 2024 & 2030
  • Fig. 53 Hospitals and clinics market, 2018 - 2030 (USD Million)
  • Fig. 54 Specialty centers market, 2018 - 2030 (USD Million)
  • Fig. 55 Homecare setting market, 2018 - 2030 (USD Million)
  • Fig. 56 Ambulatory care centers market, 2018 - 2030 (USD Million)
  • Fig. 57 Acute myeloid leukemia treatment market revenue, by region
  • Fig. 58 Regional marketplace: Key takeaways
  • Fig. 59 Regional marketplace: Key takeaways
  • Fig. 60 North America acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 61 U.S. country dynamics
  • Fig. 62 U.S. acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 63 Canada country dynamics
  • Fig. 64 Canada acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 65 Mexico country dynamics
  • Fig. 66 Mexico acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 67 Europe acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 68 UK country dynamics
  • Fig. 69 UK acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 70 Germany country dynamics
  • Fig. 71 Germany acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 72 France country dynamics
  • Fig. 73 France acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 74 Italy country dynamics
  • Fig. 75 Italy acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 76 Spain country dynamics
  • Fig. 77 Spain acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 78 Norway country dynamics
  • Fig. 79 Norway acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 80 Sweden country dynamics
  • Fig. 81 Sweden acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 82 Denmark country dynamics
  • Fig. 83 Denmark acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 84 Asia Pacific acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 85 Japan country dynamics
  • Fig. 86 Japan acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 87 China country dynamics
  • Fig. 88 China acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 89 India country dynamics
  • Fig. 90 India acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 91 Australia country dynamics
  • Fig. 92 Australia acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 93 South Korea country dynamics
  • Fig. 94 South Korea acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 95 Thailand country dynamics
  • Fig. 96 Thailand acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 97 Latin America acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 98 Brazil country dynamics
  • Fig. 99 Brazil acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 100 Argentina country dynamics
  • Fig. 101 Argentina acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 102 MEA acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 103 South Africa country dynamics
  • Fig. 104 South Africa acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 105 Saudi Arabia country dynamics
  • Fig. 106 Saudi Arabia acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 107 UAE country dynamics
  • Fig. 108 UAE acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 109 Kuwait country dynamics
  • Fig. 110 Kuwait acute myeloid leukemia treatment market, 2018 - 2030 (USD Million)
  • Fig. 111 Company categorization
  • Fig. 112 Company market position analysis
  • Fig. 113 Strategic framework